Drugs and patents in ATC class A08 - ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

Last updated: February 19, 2026

Executive Summary

The market for antiobesity preparations, excluding dietary products (ATC Class A08), is characterized by evolving scientific understanding, ongoing patent challenges, and increasing regulatory scrutiny. Recent approvals of novel GLP-1 receptor agonists have significantly reshaped the competitive landscape, driving revenue growth and sparking renewed R&D investment. However, patent expiries for older drugs and the emergence of new therapeutic modalities present both opportunities and threats for stakeholders. The patent landscape reflects a dynamic interplay between innovation in drug discovery and strategic patent management aimed at extending market exclusivity.

What are the Key Trends in the Antiobesity Preparations Market?

The global market for antiobesity preparations (excluding dietary products) has experienced substantial growth, driven by rising obesity prevalence and the introduction of more effective therapeutic agents. Market expansion is projected to continue, fueled by unmet clinical needs and advancements in drug development.

Key Market Drivers:

Increasing Obesity Prevalence: Global rates of overweight and obesity continue to rise, creating a large and growing patient population requiring medical intervention. The World Health Organization (WHO) reported that in 2022, more than 1 in 8 adults worldwide were living with obesity [1].
Advancements in Pharmacotherapy: The development and approval of drugs targeting specific biological pathways, such as GLP-1 receptor agonists, have significantly improved treatment efficacy. These newer agents offer substantial weight loss compared to previous generations of antiobesity medications.
Growing Awareness and Demand: Increased public and medical community awareness of the health risks associated with obesity is driving demand for evidence-based pharmacological treatments.
Reimbursement Policies: Evolving insurance coverage and reimbursement policies for weight-loss medications are increasingly supporting patient access, further stimulating market demand.

Market Segmentation:

The market can be segmented by drug class, mechanism of action, and patient demographics.

Drug Classes:
- GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide, tirzepatide)
- Gastrointestinal Lipase Inhibitors (e.g., orlistat)
- Appetite Suppressants (e.g., phentermine, bupropion/naltrexone)
- Others
Mechanism of Action:
- Appetite Suppression
- Increased Satiety
- Reduced Calorie Absorption
- Metabolic Modulation

Projected Market Growth:

The global antiobesity drugs market size was valued at approximately USD 2.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of over 10% from 2023 to 2030 [2]. This growth is largely attributable to the success of newer drug classes, particularly GLP-1 receptor agonists, which are demonstrating significant efficacy and safety profiles.

What is the Current Patent Landscape for Antiobesity Preparations?

The patent landscape for antiobesity preparations is a critical determinant of market exclusivity and competitive strategy. It is characterized by a mix of innovator patents on new molecular entities (NMEs), process patents, formulation patents, and method-of-use patents. The expiration of key patents opens doors for generic competition, while ongoing litigation and the development of follow-on drugs shape future market dynamics.

Key Patent Holders and Innovator Drugs:

Major pharmaceutical companies hold significant patent portfolios in this therapeutic area. Novo Nordisk, Eli Lilly, and Pfizer are prominent players with NMEs that have reshaped the market.

Semaglutide (Ozempic, Wegovy): Developed by Novo Nordisk, semaglutide is a GLP-1 receptor agonist that has demonstrated substantial weight loss. Key patents cover the molecule itself, specific salt forms, and methods of treatment.
Tirzepatide (Mounjaro): Developed by Eli Lilly, tirzepatide is a dual GLP-1 and GIP receptor agonist. Its combination mechanism offers enhanced efficacy in weight management. Patents cover the dual-acting molecule and its therapeutic applications.
Liraglutide (Saxenda): Also from Novo Nordisk, liraglutide is an earlier generation GLP-1 receptor agonist used for weight management. Patents for liraglutide have begun to expire, leading to potential generic entry.
Bupropion/Naltrexone (Contrave): Developed by Currax Pharmaceuticals, this combination drug targets appetite and craving. Patents cover the specific combination and its uses.
Orlistat (Xenical, Alli): While an older drug, patents related to specific formulations and extended-release mechanisms may still be relevant.

Patent Expiration Trends:

The impending or recent expiration of patents for established antiobesity drugs can lead to significant market shifts.

Drug Name	Active Ingredient(s)	Primary Innovator	Approximate Key Patent Expiration (US)	Impact
Liraglutide (Saxenda)	Liraglutide	Novo Nordisk	Late 2020s	Potential for generic competition, leading to price reductions and increased accessibility.
Orlistat (Xenical)	Orlistat	Roche	Already expired for basic molecule	Generic versions are available. Newer formulations or specific methods of use might still be under patent protection.
Phentermine	Phentermine	Various	Expired	Widely available as a generic.
Bupropion/Naltrexone	Bupropion HCl/Naltrexone HCl	Currax	Mid-2030s (expected)	Patents on the combination and specific formulations provide extended exclusivity.
Semaglutide (Wegovy)	Semaglutide	Novo Nordisk	Mid-2030s (expected)	Strong patent protection is anticipated for the molecule and its formulations, delaying generic entry significantly.
Tirzepatide (Mounjaro)	Tirzepatide	Eli Lilly	Mid-2030s (expected)	Similar to semaglutide, robust patent protection is expected for this novel dual agonist, securing market exclusivity for an extended period.

Note: Patent expiration dates are approximate and can vary based on jurisdiction, patent extensions (e.g., Hatch-Waxman extensions in the US), and specific patent claims. This table focuses on general trends.

Patent Litigation and Challenges:

The antiobesity drug market is subject to patent litigation, including challenges to patent validity and inventorship disputes. These legal battles can significantly impact market exclusivity timelines. For instance, challenges to the patents protecting blockbuster drugs like semaglutide could, if successful, lead to earlier generic entry. Conversely, successful defense of these patents solidifies the innovator's market position.

Emerging Technologies and Patent Filings:

Beyond small molecules, the patent landscape is evolving to include:

Biologics: Long-acting peptide-based therapies and antibody-based treatments targeting weight management are subjects of new patent filings.
Combination Therapies: Patents are being filed for novel combinations of existing or new agents to achieve synergistic effects.
Delivery Systems: Innovations in drug delivery, such as sustained-release formulations or novel injection devices, are also patented to enhance patient compliance and therapeutic outcomes.

What are the Intellectual Property Strategies for Antiobesity Preparations?

Pharmaceutical companies employ multifaceted intellectual property (IP) strategies to maximize market exclusivity and return on investment for their antiobesity drug candidates. These strategies are crucial in a competitive landscape where the high cost of R&D necessitates a protected market period.

Key IP Strategies:

Composition of Matter Patents:
- These are the most fundamental patents, protecting the novel active pharmaceutical ingredient (API) itself. They offer the longest period of exclusivity and are essential for any new drug. For NMEs like semaglutide and tirzepatide, these patents form the bedrock of their IP protection.
- Example: A patent claiming the specific chemical structure of a novel GLP-1 analog.
Formulation Patents:
- These patents protect specific ways the drug is formulated for administration, such as extended-release tablets, specific salt forms, or nanoparticle formulations. They can extend market exclusivity even after the primary composition of matter patent expires.
- Example: A patent on a once-weekly injectable formulation of a peptide therapeutic that improves stability and patient convenience.
Method of Use Patents:
- These patents claim the use of a known or new compound for treating a specific condition, such as obesity, or a specific sub-population of obese patients. Method of use patents can be crucial for repurposing existing drugs or extending the life of a drug by identifying new indications.
- Example: A patent claiming the use of a specific drug for treating obesity in patients with type 2 diabetes.
Process Patents:
- These patents protect the specific methods or processes used to synthesize the API or manufacture the drug product. While generally weaker than composition of matter patents, they can deter generic manufacturers from using the most efficient production routes.
- Example: A patent describing a novel synthetic pathway that yields a higher purity of the active ingredient.
Patent Term Extensions (PTEs) and Supplementary Protection Certificates (SPCs):
- Regulatory mechanisms like PTEs in the U.S. and SPCs in Europe allow for the extension of patent protection to compensate for the time lost during the regulatory review process. This is a critical tool to recoup R&D investments.
- Example: A drug approved in 2025 with a 7-year PTE could extend its market exclusivity until 2037, assuming a 10-year patent was granted earlier.
Evergreening Strategies:
- This involves filing a series of new patents on incremental improvements to an existing drug. This can include new formulations, delivery devices, dosages, or new methods of use. While controversial, it is a common strategy to extend the commercial life of a successful drug.
- Example: Filing patents on different dosage strengths or combinations of an approved antiobesity drug to create new product variations.
Data Exclusivity:
- Regulatory agencies grant periods of data exclusivity upon approval of NMEs, independent of patent protection. This prevents generic manufacturers from relying on the innovator's clinical trial data to gain approval for their own versions.
- Example: In the U.S., NMEs typically receive 5 years of data exclusivity, which can be extended to 5.5 years if the drug is a "new chemical entity."

Challenges and Considerations:

Patent Cliffs: The expiration of foundational patents creates "patent cliffs," where revenue can drop dramatically due to generic competition. Companies must plan for this by developing new pipeline drugs or leveraging other IP strategies.
Litigation Risk: Innovator companies face constant threats of patent litigation from generic manufacturers seeking to invalidate patents or challenge their enforceability.
Global Harmonization: Patent laws and enforcement vary significantly across different jurisdictions, requiring a complex global IP strategy.

What are the Regulatory Considerations for Antiobesity Preparations?

The regulatory pathway for antiobesity preparations is stringent, reflecting the chronic nature of the condition and the potential for systemic side effects. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require robust evidence of both efficacy and safety.

Key Regulatory Aspects:

Clinical Trial Requirements:
- Efficacy: Demonstrating statistically significant and clinically meaningful weight loss is paramount. This typically involves trials comparing the drug to placebo or an active comparator. Weight loss endpoints usually include percentage of body weight lost and the proportion of patients achieving ≥5% or ≥10% weight loss.
- Safety: Long-term safety data is critical, particularly for chronic use. Potential adverse events, including cardiovascular effects, gastrointestinal issues, and psychiatric effects, are closely monitored.
- Specific Populations: Trials often need to demonstrate efficacy and safety in specific patient populations, such as those with comorbidities like type 2 diabetes or cardiovascular disease.
Approvals and Labeling:
- Indications: Drugs are approved for specific indications, often described as adjunctive to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity.
- Black Box Warnings: Some antiobesity drugs may carry black box warnings highlighting significant risks, requiring careful patient selection and monitoring.
- Risk Evaluation and Mitigation Strategies (REMS): In some cases, REMS programs are implemented to manage specific risks associated with the drug.
Post-Market Surveillance:
- Regulatory agencies continue to monitor the safety and effectiveness of antiobesity drugs after approval through pharmacovigilance systems.
- Example: The FDA's MedWatch program collects reports of adverse events from healthcare professionals and the public.
Generic Drug Approval (ANDA):
- For generic antiobesity drugs, manufacturers must submit an Abbreviated New Drug Application (ANDA) to the FDA. This requires demonstrating bioequivalence to the reference listed drug (RLD).
- Patent Certifications: ANDA submissions involve certifications regarding the patent status of the RLD. Generic companies must certify that relevant patents have expired, are invalid, or will not be infringed.
Interchangeability:
- For biological products (though less common in current antiobesity small molecule market), regulatory approval also considers interchangeability, allowing for substitution by pharmacists. This is a higher bar than mere bioequivalence.

Recent Regulatory Trends:

Increased Scrutiny of Cardiovascular Safety: Following earlier concerns with some older weight-loss drugs, there is heightened scrutiny on the cardiovascular safety profile of new antiobesity medications. Large cardiovascular outcome trials (CVOTs) are often a requirement or are voluntarily conducted by manufacturers. For example, Novo Nordisk's SELECT trial for semaglutide demonstrated a reduction in major adverse cardiovascular events [3].
Focus on Long-Term Efficacy and Safety: As obesity is a chronic condition, regulatory bodies are increasingly focused on the long-term sustainability of weight loss and the ongoing safety of these medications.
Guidance on Real-World Evidence (RWE): Agencies are exploring the use of RWE from electronic health records, insurance claims, and patient registries to supplement clinical trial data for post-market safety monitoring and understanding drug utilization patterns.

Key Takeaways

The antiobesity preparations market is experiencing robust growth driven by rising obesity rates and the advent of highly effective GLP-1 receptor agonists.
Novo Nordisk (semaglutide, liraglutide) and Eli Lilly (tirzepatide) are dominant players with significant patent portfolios protecting their blockbuster drugs.
Patent expiries for older medications like liraglutide are creating opportunities for generic competition, while strong patent protection for newer agents is expected to maintain innovator exclusivity well into the mid-2030s.
Companies employ comprehensive IP strategies, including composition of matter, formulation, and method of use patents, alongside regulatory mechanisms like PTEs, to secure market exclusivity.
Regulatory pathways are rigorous, demanding substantial evidence of efficacy and long-term safety, with increasing focus on cardiovascular outcomes and post-market surveillance.

Frequently Asked Questions

What is the primary mechanism of action for the most successful antiobesity drugs currently on the market? The most successful antiobesity drugs, such as semaglutide and tirzepatide, primarily act as agonists for glucagon-like peptide-1 (GLP-1) receptors. Tirzepatide also acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. These mechanisms lead to increased satiety, reduced appetite, and delayed gastric emptying, contributing to significant weight loss.
How do patent expiries for older antiobesity drugs impact market competition? Patent expiries allow generic manufacturers to produce and market bioequivalent versions of the expired drug. This typically leads to a significant decrease in price, increased market accessibility for patients, and a reduction in revenue for the original innovator. For example, the anticipated expiry of liraglutide patents will likely usher in generic competition.
What are the key challenges in obtaining regulatory approval for new antiobesity medications? Key challenges include demonstrating statistically significant and clinically meaningful weight loss over an extended period, establishing a favorable long-term safety profile (especially concerning cardiovascular and psychiatric effects), and meeting the stringent requirements for clinical trial design and data analysis mandated by regulatory bodies like the FDA and EMA.
How does intellectual property strategy differ for small molecule antiobesity drugs compared to biologics? For small molecules, composition of matter patents on the API are paramount. For biologics, patents typically cover the protein sequence, specific modifications, manufacturing processes, and formulations. Both require robust patenting of therapeutic uses and delivery methods, but the complexity of manufacturing and characterization for biologics necessitates a broader IP approach, including patenting the cell lines and production methods.
What role does real-world evidence (RWE) play in the regulatory and market landscape of antiobesity preparations? RWE is increasingly used for post-market surveillance to monitor long-term safety and effectiveness in diverse patient populations beyond clinical trial participants. It can also inform prescribing decisions, identify unmet needs, and potentially influence future regulatory guidance or label updates. For example, RWE can help understand how weight management drugs perform in patients with various comorbidities.

Citations

[1] World Health Organization. (2022). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

[2] Grand View Research. (2023). Obesity treatment market size, share & trends analysis report by drug class (GLP-1 agonists, lipase inhibitors, appetite suppressants), by drug type (branded, generic), by distribution channel (hospital pharmacy, retail pharmacy, online pharmacy), by region, and segment forecasts, 2023-2030.

[3] Novo Nordisk. (2023, November 4). SELECT trial results show semaglutide 2.4 mg significantly reduces risk of major adverse cardiovascular events in adults with overweight or obesity. https://www.novonordisk.com/media/news-releases/select-trial-results-show-semaglutide-2.4-mg-significantly-reduces-risk-of-major-adverse-cardiovascular-events.html

Drugs in ATC Class A08

Subclasses in ATC: A08 - ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

Patent Landscape and Market Dynamics: Antiobesity Preparations (ATC A08)